AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04629144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Both arms will have the same corticosteroid tapering scheme, with an initial dose of 30 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~* 30 mg/day week (W)0-W2,~* 20 mg/day W2-W4~* 15 mg/day W4-W6,~* 10 mg/day W6-W8,~* 5 mg/day W8-W10~Between W10-W12 the strategy for stopping glucocorticoids is left to the investigator's discretion.~Stopping glucocorticoid therapy at W12. At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity.
Study NCT05934097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT596
Description: Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously
Study NCT05934097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 intravenously
Study NCT05934097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 intravenously
Study NCT05934097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2 (maximum dose 2 mg) intravenously
Study NCT05934097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg orally
Study NCT05934097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenously
Study NCT05934097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 IV infusion
Study NCT05690022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Description: Patients will be recruited for a sleeve gastrectomy according to the guidelines of the National Institute of Health.
Study NCT06443671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CapeOX
Description: Receiving CapeOX treatment for up to four cycles before surgery:~Capecitabine: 1000mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 130 mg/m2, intravenous drip for 0-2 hours, D1, Q3W.
Study NCT06443671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib and Tislelizumab combined with mCapeOX
Description: Receiving Fruquintinib plus Tislelizumab combined with mCapeOX treatment for up to four cycles before surgery:~Fruquintinib: 3mg/d, QD, PO, Use for 2 weeks, stop for 1 week, Q3W; Tislelizumab: 200mg, D1, Intravenous infusion, Q3W; Capecitabine: 825mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 100 mg/m2, intravenous drip for 0-2 hours, D1, Q3W.
Study NCT05687942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBUILD
Description: 3.1.1. REBUILD is an investigational medical device provided as a sterile, single use set containing 10 suture Anchors and two non-implantable Carriers, with reusable stainless-steel instruments for deployment supplied separately.
Study NCT04803084 — intervention group
Intervention type: OTHER
Intervention: Tempus assay
Description: Blood collection
Study NCT04803084 — intervention group
Intervention type: OTHER
Intervention: Advanced pathology 1
Description: Tissue procurement (from diagnostic biopsy)
Study NCT04803084 — intervention group
Intervention type: OTHER
Intervention: Advanced pathology 2
Description: Tissue procurement (from research biopsy)
Study NCT06297564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone primed endometrial protocol
Description: The cases were received soft progesterone capsules (brand name: Utrogestan, 100 mg, Laboratories Besins International, France) 100 mg and 150 IU of human menopausal gonadotropin (hMG) concomitantly from the menstrual cycle (MC) day 3 until the trigger day.
Study NCT06297564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone antagonist protocol
Description: The cases were received the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol consisting of HMG 150 IU's daily injection from MC 3 until the trigger day. GnRH-ant (Cetrotide, 0.25 mg, MerckSerono) was started when at least one of the following criteria were met: LH >10 IU/L, the presence of at least one follicle with mean diameter >14 mm, or serum E2 level >600 pg/mL.
Study NCT06483984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Respiratory support with a facemask connected to a ventilator through a heated humidifier. Ventilator will be set in the pressure support mode.
Study NCT06483984 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: Respiratory support with a facemask connected to a ventilator through a heated humidifier. Ventilator will be set in the pressure support mode.
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 3 (I x E x S x F)
Description: Experimental message: Individual x Effectiveness x Storytelling x Factual
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 4 (O x E x S x F)
Description: Experimental message: Organization x Effectiveness x Storytelling x Factual
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 5 (I x S x S x M)
Description: Experimental message: Individual x Safety x Storytelling x Misinformation
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 6 (O x S x S x M)
Description: Experimental message: Organization x Safety x Storytelling x Misinformation
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 7 (I x E x S x M)
Description: Experimental message: Individual x Effectiveness x Storytelling x Misinformation
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 8 (O x E x S x M)
Description: Experimental message: Organization x Effectiveness x Storytelling x Misinformation
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 9 (I x S x D x F)
Description: Experimental message: Individual x Safety x Scientific data x Factual
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 10 (O x S x D x F)
Description: Experimental message: Organization x Safety x Scientific data x Factual
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 11 (I x E x D x F)
Description: Experimental message: Individual x Effectiveness x Scientific data x Factual
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 12 (O x E x D x F)
Description: Experimental message: Organization x Effectiveness x Scientific data x Factual
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 13 (I x S x D x M)
Description: Experimental message: Individual x Safety x Scientific data x Misinformation
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 14 (O x S x D x M)
Description: Experimental message: Organization x Safety x Scientific data x Misinformation
Study NCT06614803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation combined slow breathing
Description: The stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear,the screen of the device displays slow breathing guidance video at 0.1Hz, while the device delivered stimulation during the 5 seconds of exhalation.
Study NCT06614803 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: Without slow breathing guidance video on the stimulation device,the stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear
Study NCT06614803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: Without slow breathing guidance video on the stimulation device,the stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 15 (I x E x D x M)
Description: Experimental message: Individual x Effectiveness x Scientific data x Misinformation
Study NCT06347627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 16 (O x E x D x M)
Description: Experimental message: Organization x Effectiveness x Scientific data x Misinformation
Study NCT05511935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: professional development training for CHWs on dental health (GRIN)
Description: multi module online training
Study NCT06613386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The information-based discharge preparation service (IBDPS)
Description: The main modules of the IBDPS platform include:~* Establishing information records for infants and parents.~* Collaboratively identifying existing or potential caregiving challenges.~* Assessing parents' emotional and psychological states, providing support and intervention.~* Collaboratively establishing caregiving objectives with parents.~* Collaboratively formulating and executing caregiving plans.~* Assessing parental support resources, offering analysis, assistance, and necessary referrals.~* Conducting outcome assessments.
Study NCT06614153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRG2010(I)
Description: HRG2010(I)
Study NCT06614153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRG2010(II)
Description: HRG2010(II)
Study NCT06614153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-release Carbidopa/Levodopa
Description: Sustained-release Carbidopa/Levodopa
Study NCT06614452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-FNB
Description: Endoscopic ultrasound will be performed using a curvilinear array echoendoscope. FNB with 22G or 25G end-cutting needles will be performed. The size of the needles will be based on the personal choice of the endoscopist. Likewise, the sampling technique, whether using the slow-pull, the dry suction, or the wet suction, will be based on the physician's choice. Three passes will be performed as per current guidelines. Specimens will be collected in 3 vials to allow for analysis according to needle pass; one for the first pass, one for the second pass, and one for the third and any eventual subsequent passes.~The rapid-on site cytological evaluation (ROSE) will not be available in this study.
Study NCT06615414 — intervention group
Intervention type: OTHER
Intervention: participants are not assigned an intervention as part of the study
Description: participants are not assigned an intervention as part of the study
Study NCT06528782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pecha Kucha method
Description: The Pecha Kucha method will be prepared in the form of a presentation consisting of 20 slides each shown for 20 seconds. The Pecha Kucha presentation lasts 6 minutes and 40 seconds, and most slides present only images. This method is planned to be used in breastfeeding education as it will be more memorable because it contains more visual, auditory and short information.
Study NCT06688708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using vibrating foot orthosis with tactile stimulation
Description: Stimulating tactile sensation by using vibrating foot orthosis in conjunction with a random 0-100 Hz square wave pulse stimulus and pseudorandom white noise via a stochastic resonance approach.
Study NCT06688708 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Using vibrating foot orthosis without tactile stimulation
Description: Stimulating tactile sensation by using vibrating foot orthosis with only vibration 100 Hz freqency.
Study NCT06290193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution/ANH
Description: For participants randomized to ANH, the volume of blood to be removed will be calculated using an established formula, based on preoperative hemoglobin, target hemoglobin after hemodilution, and the patient's estimated blood volume.
Study NCT06696937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: Tai chi is a practice that involves a series of slow gentle movements and physical postures, a meditative state of mind, and controlled breathing. Tai chi originated as an ancient martial art in China. Over the years, it has become more focused on health promotion and rehabilitation.
Study NCT06696937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: full body vibrator
Description: Advocates say that as little as 15 minutes a day of whole-body vibration three times a week may aid weight loss, burn fat, improve flexibility, enhance blood flow, reduce muscle soreness after exercise, build strength and decrease the stress hormone cortisol.
Study NCT06696742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Butyricum Tablets
Description: Gemcitabine and Cisplatin combined with Clostridium Butyricum Tablets
Study NCT06696742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Gemcitabine and Cisplatin
Study NCT05381753 — intervention group
Intervention type: DRUG
Intervention: Avapritinib
Description: Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.
Study NCT05381753 — intervention group
Intervention type: DRUG
Intervention: Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
Description: Investigators will decide which TKI to use as well as the dosage, frequency, and duration.
Study NCT06696547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Coil
Study NCT06696547 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Sham Coil
Study NCT05898594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-dose Computed Tomography
Description: Per standard care
Study NCT06697665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LM103
Description: Patients were treated with PD-1, cyclophosphamide and fludarabine, LM103 and IL-2 treatment.
Study NCT04963413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
Description: Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
Study NCT04919590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: This is Quitting
Description: Text message-based intervention for quit vaping support.
Study NCT06696235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early initiation of continuous renal replacement therapy
Description: Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
Study NCT06696235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard initiation of continuous renal replacement therapy
Description: Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
Study NCT06696495 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of the size and width of the foot
Description: Assessment of the height of the plantar arch using a podoscope, and application of functional scales such as the AOFAS (Ankle and Foot Outcome Score), the FPI (Foot Posture Index) and the FFI (Foot Function Index). In addition, the distribution of plantar pressure and the centre of pressure (COP)
Study NCT06697223 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: INTERCEPT Blood System for Platelets with LED Illuminator
Description: Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) using the LED Illuminator and stored for 5 days at 20 to 24°C with continuous agitation.
Study NCT04689048 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 18F fluciclovine
Description: Patients will receive a standard 5 millicuries dose of 18F-fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
Study NCT06396195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bioflx crown
Description: The Bioflx crowns are characterized by their flexibility, durability, and adaptability. These crowns are preformed pediatric crowns designed for aesthetics, combining properties found in both stainless steel and zirconia crowns.
Study NCT06396195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stainless steel crown
Description: Stainless steel crowns continue to be considered the Gold Standard for posterior full coverage restorations in primary molars
Study NCT04919590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment only control
Description: Assessment only
Study NCT04919590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: No contact until follow-up survey, waitlisted to receive intervention post study
Study NCT04922021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is an antibody given by injection just under the skin.
Study NCT06512038 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: DEXA Scan
Description: If the participant consents to take part in the trial, they will have an additional DEXA scan.
Study NCT04969770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound elastography (USE)
Description: Visualization of the vertebral disc and the para-vertebral muscles.~Intra and inter observer reproducibility analysis carried out for each of the measurements made, by two operators.~Patients with instrumented neuromuscular scoliosis: 5 elastographies : preoperatively, then during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Patients with neuromuscular pathologies without instrumented scoliosis: 4 elastographies during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Healthy control patients without neuromuscular pathology or scoliosis :~1 elastography during an usual consultation.
Study NCT04969770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound elastography (USE)
Description: Visualization of the vertebral disc and the para-vertebral muscles.~Intra and inter observer reproducibility analysis carried out for each of the measurements made, by two operators.~Patients with instrumented neuromuscular scoliosis: 5 elastographies : preoperatively, then during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Patients with neuromuscular pathologies without instrumented scoliosis: 4 elastographies during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Healthy control patients without neuromuscular pathology or scoliosis :~1 elastography during an usual consultation.
Study NCT06380400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot bath
Description: Pregnant women were given footbaths for 20 minutes during the active phase of the first stage of labour (after cervical dilatation of 4 cm) and 20 minutes during the transitional phase of the second stage of labour (cervical dilatation of 9 cm). Pregnant women who completed two footbath sessions were assessed for pain using the visual comparison scale. In addition, the data collection process will be completed by applying the Birth Comfort Scale after the two stages of labour.
Study NCT05611684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol Losenatide
Description: Treatment 0.2mg QW for 12 weeks
Study NCT05312905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy
Description: Mirror Therapy applied alone
Study NCT05312905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy + Cognitive Therapy
Description: Mirror Therapy supported with Cognitive Exercises
Study NCT03000803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Total Caloric Intake
Description: Provide subjects a regimented amount of calories at each meal.
Study NCT03000803 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Late Total Caloric Intake
Description: Provide subjects a regimented amount of calories at each meal.
Study NCT06497426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study intervention
Description: Participants will be asked to drink water. Water intake will be supervised by a nurse/nurse assistant/dietitian team to ensure adherence, and registered to assess intervention compliance.